SCHEDULE: Spectrum Equity Reduces GoodRx Stake to 8.28%

Spectrum Equity entities have reduced their beneficial ownership in GoodRx Holdings, Inc. to 8.28% following a pro rata distribution and subsequent open market sales.

Summary

• Spectrum Equity VII, L.P. (SE VII) distributed 5,983,984 shares of GoodRx Class A Common Stock pro rata to its limited partners on September 4, 2025, for no consideration.
• Following this distribution, Spectrum VII Co-Investment Fund, L.P. and Spectrum VII Investment Managers' Fund, L.P. sold an aggregate of 16,016 Class A Common Stock shares in open market transactions.
• These sales generated net proceeds of $64,864.80.
• The Reporting Persons (Spectrum Equity entities) now collectively beneficially own 8,905,133 shares of GoodRx Class A Common Stock, representing 8.28% of the outstanding Class A Shares on an as-converted basis.
• This percentage is calculated based on 98,580,674 Class A Shares outstanding as of July 29, 2025, plus the 8,905,133 Class B Shares held by the Reporting Persons (convertible 1:1).

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to the reduction in a significant institutional investor's stake, which can be interpreted as a lack of future conviction, despite being a routine portfolio management activity for private equity firms.

Positives

• The pro rata distribution of shares to limited partners by SE VII can be viewed as a return of capital to investors or a strategic portfolio management decision by Spectrum Equity.

Negatives

• The open market sale of 16,016 shares by two Spectrum Equity funds represents a direct reduction in their investment in GoodRx.
• The overall reduction in Spectrum Equity's beneficial ownership to 8.28% could be interpreted by the market as a decrease in conviction or a strategic move towards a full exit by a significant institutional investor.

Future Outlook

The filing does not provide any forward-looking statements or guidance regarding GoodRx's future performance or Spectrum Equity's future investment intentions beyond the described transactions.

Industry Context

This filing reflects a private equity firm's ongoing portfolio management activities, specifically a reduction in its stake in a publicly traded digital healthcare company. Such distributions and sales are common as funds mature and seek to return capital to limited partners or rebalance their portfolios. It does not inherently indicate a broader industry trend but rather a specific investor's strategic decision regarding GoodRx.

Stakeholder Impact

• Shareholders: The reduction in a significant institutional stake could lead to negative market sentiment and potentially downward pressure on the stock price, especially if other investors interpret it as a signal of reduced confidence in GoodRx's future prospects.
• Spectrum Equity Limited Partners: Received a pro rata distribution of GoodRx shares, providing them with direct ownership or liquidity options.

Key Dates

Recommendation

While the reduction in a significant institutional stake by Spectrum Equity could be perceived negatively, it is a common practice for private equity firms to divest holdings over time. The filing itself does not provide new fundamental information about GoodRx's operations or financial health. Investors should 'hold' and monitor GoodRx's operational performance and future financial reports rather than reacting solely to this ownership change, which is more indicative of the investor's portfolio management strategy than a direct commentary on GoodRx's intrinsic value.

Keywords

GoodRx Holdings, Spectrum Equity, GRX, Schedule 13D/A, Share Distribution, Stock Sale, Beneficial Ownership, Institutional Investor, Private Equity